An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
Clinical trial NCT04671849 · UNKNOWN
Trial details
- NCT number
- NCT04671849
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-21
- Primary completion
- 2022-09-30
- Enrollment
- 243
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.